Get the Stockscreener App
3.40
1.19%
0.04
After Hours:
3.76
0.36
+10.59%
Ac Immune Sa stock is traded at $3.40, with a volume of 45,463.
It is up +1.19% in the last 24 hours and up +12.96% over the past month.
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
See More
Previous Close:
$3.36
Open:
$3.4
24h Volume:
45,463
Relative Volume:
0.44
Market Cap:
$336.41M
Revenue:
-
Net Income/Loss:
$-60.14M
P/E Ratio:
-3.9813
EPS:
-0.854
Net Cash Flow:
$-68.17M
1W Performance:
+0.59%
1M Performance:
+12.96%
6M Performance:
-7.36%
1Y Performance:
+5.92%
1-Day Range:
$3.345
$3.41
1-Week Range:
$3.29
$3.48
52-Week Range:
$2.25
$5.14
Ac Immune Sa Stock (ACIU) Company Profile
Compare ACIU with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ACIU
Ac Immune Sa
|
3.40 | 336.41M | 0 | -60.14M | -68.17M | -0.7095 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.13 | 120.56B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
750.22 | 82.44B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
616.55 | 36.87B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.07 | 32.64B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
118.39 | 28.38B | 3.30B | -501.07M | 1.03B | -2.1146 |
Ac Immune Sa Stock (ACIU) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-31-24 | Initiated | BTIG Research | Buy |
| Feb-01-19 | Downgrade | UBS | Buy → Neutral |
| Jan-04-19 | Initiated | UBS | Buy |
| Apr-05-18 | Initiated | H.C. Wainwright | Buy |
| Mar-23-18 | Downgrade | Credit Suisse | Outperform → Neutral |
| Oct-18-16 | Initiated | Credit Suisse | Outperform |
| Oct-18-16 | Initiated | Jefferies | Buy |
| Oct-18-16 | Initiated | Leerink Partners | Outperform |
View All
Ac Immune Sa Stock (ACIU) Latest News
AC Immune Q3 2024: Strong Progress and Financial Turnaround - TipRanks
HC Wainwright Reaffirms “Buy” Rating for AC Immune (NASDAQ:ACIU) - Defense World
AC Immune’s stock jumps after Parkinson’s therapy shows signs of benefit - Clinical Trials Arena
AC Immune (NASDAQ:ACIU) Given "Buy" Rating at HC Wainwright - MarketBeat
AC Immune reports interim results from Phase 2 trial of ACI-7104.056 - Yahoo Finance
AC Immune (ACIU) Sees Stock Boost Following Positive Trial Data - Stocks Telegraph
Short Interest in AC Immune SA (NASDAQ:ACIU) Increases By 23.5% - MarketBeat
AC Immune SA (NASDAQ:ACIU) Short Interest Up 23.5% in October - Defense World
AC Immune stock jumps 20% on data for Parkinson's disease drug (NASDAQ:ACIU) - Seeking Alpha
S&P 500 Moves Lower; US Crude Oil Inventories Increase - Benzinga
AC Immune's Active Immunotherapy Shows Antibody Responses In Early Parkinson's Patients - Benzinga
AC Immune Phase II ACI-7104.056 success in Parkinson’s - The Pharma Letter
AC Immune's Parkinson's vaccine shows promise in early trial - Investing.com India
AC immune announces positive trial results for early Parkinson’s treatment - PharmaTimes
AC Immune’s Promising Trial Results for Parkinson’s Therapy - TipRanks
Immunotherapy in Early Parkinson’s Disease Posts Positive Interim Results from Phase 2 Study - Precision Vaccinations
AC Immune Reports Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson's Disease - The Manila Times
AC Immune's Parkinson's vaccine shows promise in early trial By Investing.com - Investing.com UK
AC Immune's Parkinson's Drug Shows 16x Higher Antibody Levels in Phase 2 Trial | ACIU Stock News - StockTitan
Finansavisen - Finansavisen
AC Immune to Present at Jefferies Healthcare Conference: Key Investor Updates Coming | ACIU Stock News - StockTitan
AC Immune to Present at the Jefferies 2024 London Healthcare Conference - Informazione.it
Climb Bio Reports Third Quarter 2024 Financial Results and Business Highlights - The Manila Times
Climb Bio Appoints Douglas E. Williams, Ph.D., as Chair of the Board - The Manila Times
AC Immune SA Beat Analyst Profit Forecasts, And Analysts Have New Estimates - Yahoo Finance
Leerink Partnrs Increases Earnings Estimates for AC Immune - Defense World
FY2024 EPS Estimates for AC Immune Lifted by Leerink Partnrs - MarketBeat
FY2024 EPS Estimates for AC Immune Boosted by HC Wainwright - MarketBeat
HC Wainwright Reaffirms Buy Rating for AC Immune (NASDAQ:ACIU) - Defense World
Brokers Set Expectations for AC Immune FY2027 Earnings - MarketBeat
HC Wainwright Reiterates "Buy" Rating for AC Immune (NASDAQ:ACIU) - MarketBeat
AC Immune SA Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
AC Immune: Q3 Earnings Snapshot - San Francisco Chronicle
AC Immune reports Q3 EPS CHF 0.05 vs (CHF 0.18) last year - TipRanks
AC Immune SA Reports Profitable Q3 2024 Results - TipRanks
AC Immune Reports Third Quarter 2024 Financial Results and Provides a Corporate Update - The Manila Times
Will ABATE Trial Data Lift AC Immune's Stock Price? - RTTNews
Assenagon Asset Management S.A. Has $846,000 Stock Position in AC Immune SA (NASDAQ:ACIU) - MarketBeat
Short Interest in AC Immune SA (NASDAQ:ACIU) Decreases By 7.4% - MarketBeat
AC Immune SA (NASDAQ:ACIU) stock most popular amongst individual investors who own 32%, while private equity firms hold 29% - Yahoo Finance
What To Expect From AC Immune SA (ACIU) Q3 2024 Earnings - Yahoo Finance
Roche leaves Alzheimer partnership with UCB - European Biotechnology News
UCB Assessing Bepranemab’s Future After Roche/Genentech Ends Partnership - Citeline
Scrip Asks…What Does 2023 Hold For Biopharma? Part 5: Technological Advances - Citeline News & Insights
AC Immune SA (NASDAQ:ACIU) Sees Significant Increase in Short Interest - MarketBeat
AC Immune SA (NASDAQ:ACIU) Short Interest Up 12.9% in September - MarketBeat
AC Immune (NASDAQ:ACIU investor three-year losses grow to 47% as the stock sheds US$40m this past week - Simply Wall St
Renaissance Technologies LLC Has $2.60 Million Position in AC Immune SA (NASDAQ:ACIU) - MarketBeat
AC Immune (NASDAQ:ACIU) Downgraded by StockNews.com - Defense World
AC Immune (NASDAQ:ACIU) Downgraded by StockNews.com to Hold - MarketBeat
Down Syndrome Market Forecasted to Surge in Coming Years, 2023-2032 Analysis by DelveInsight | AstraZeneca, Aelis Farma, AC Immune SA, Eisai Inc., Hoffmann-La Roche, Life Molecular Imaging SA - Barchart
Ac Immune Sa Stock (ACIU) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.61%
1.14%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):